Table 2.
Factors influencing neoadjuvant therapy response. BMI Body Mass Index, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, FISH fluorescence in situ hybridization, AR androgen receptor, pCR pathological complete response, TCHP taxanes, carboplatin, trastuzumab and pertuzumab, NPHP vinorelbine, cisplatin, trastuzumab and pertuzumab, OR odds ratio, CI confidence interval.
| B | Standard Error | Wald | Significance | OR (95% CI) | |
|---|---|---|---|---|---|
| Age | |||||
| ≤45 | |||||
| >45 | 0.202 | 1.116 | 0.033 | 0.856 | 1.224 (0.137–10.911) |
| BMI | |||||
| <18.5 | 1.035 | 0.793 | |||
| 18.5–24 | −18.216 | 26,106.954 | 0.000 | 0.999 | 0.000 |
| 24–28 | −19.632 | 26,106.954 | 0.000 | 0.999 | 0.000 |
| >28 | −39.525 | 30,878.473 | 0.000 | 0.999 | 0.000 |
| T stage | |||||
| T1–2 | |||||
| T3 | 3.354 | 2.040 | 2.704 | 0.100 | 28.614 (0.525–1558.715) |
| N stage | |||||
| N0 | |||||
| N+ | −0.997 | 1.217 | 0.671 | 0.413 | 0.369 (0.034–4.007) |
| Histological grade | |||||
| G2 | |||||
| G3 | −0.639 | 1.269 | 0.254 | 0.614 | 0.528 (0.044–6.344) |
| ER | |||||
| ER- | |||||
| ER+ | −3.939 | 2.798 | 1.982 | 0.159 | 0.019 (0–4.689) |
| PR | |||||
| PR- | |||||
| PR+ | −0.493 | 2.218 | 0.049 | 0.824 | 0.611 (0.008–47.198) |
| HER2 | |||||
| 3+ | |||||
| 2+ and FISH+ | 1.738 | 1.965 | 0.783 | 0.376 | 5.686 (0.121–267.375) |
| Ki67 | |||||
| ≤30 | |||||
| >30 | 4.730 | 2.542 | 3.462 | 0.063 | 113.247 (0.777–16,504.22) |
| AR | |||||
| 0–49 | 4.995 | 0.082 | |||
| 50–89 | 1.790 | 1.610 | 1.236 | 0.266 | 5.99 (0.255–140.57) |
| ≥90 | 6.592 | 3.070 | 4.612 | 0.032 | 729.322 (1.778–299,130.165) |
| Neoadjuvant therapy | |||||
| TCHP | |||||
| non-TCHP | −3.675 | 2.490 | 2.178 | 0.140 | 0.025 (0–3.338) |
| Constant | 16.939 | 26,106.954 | 0.000 | 0.999 | 22,733,481.85 |